Allogeneic bone marrow transplantation for patients with hematologic malignancies.
Allogeneic marrow transplantation is an effective modality for the treatment of patients with hematologic malignancies. Limitations of success are donor availability, posttransplant relapses, and transplant-related morbidity and mortality. Progress is being made in improving the results of partially HLA matched family member donor transplants and in the use of HLA matched unrelated donors. Increases in dose intensity of pretransplant regimens are limited by toxicity and in order to be effective methods need to be developed to ameliorate side effects. The use of anti-inflammatory agents and recombinant growth factors show promise in decreasing transplant-related deaths.
Buckner
C D
CD
Fred Hutchinson Cancer Research Center, Seattle, WA 98104.
Anasetti
C
C
Bianco
J
J
Nemunaitis
J
J
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000276:immunology / Q000379:methods*; D006084:Graft Rejection / Q000276:immunology / Q000628:therapy; D006086:Graft vs Host Disease / Q000276:immunology / Q000628:therapy; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006680:HLA Antigens / Q000276:immunology; D006650:Histocompatibility Testing / Q000379:methods; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007938:Leukemia / Q000276:immunology / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D014019:Tissue Donors
D000893:Anti-Inflammatory Agents; D006680:HLA Antigens; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor